Kathy Turner Net Worth

The estimated Net Worth of Kathy V Turner is at least 12 百万$ dollars as of 15 February 2023. Ms. Turner owns over 1,010 units of Idexx Laboratories stock worth over 3,617,629$ and over the last 6 years she sold IDXX stock worth over 5,645,857$. In addition, she makes 2,696,820$ as Corporate Vice President and Chief Marketing Officer at Idexx Laboratories.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Turner IDXX stock SEC Form 4 insiders trading

Kathy has made over 19 trades of the Idexx Laboratories stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 1,010 units of IDXX stock worth 515,191$ on 15 February 2023.

The largest trade she's ever made was exercising 13,877 units of Idexx Laboratories stock on 10 November 2022 worth over 2,625,945$. On average, Kathy trades about 2,661 units every 91 days since 2018. As of 15 February 2023 she still owns at least 7,379 units of Idexx Laboratories stock.

You can see the complete history of Ms. Turner stock trades at the bottom of the page.

Kathy Turner biography

Kathy V. Turner serves as Corporate Vice President and Chief Marketing Officer of the Company. Ms. Turner has been Corporate Vice President since May 2014 and leads the Company’s Europe, Middle East and Africa Companion Animal Commercial Operations, and the Company's Asia Pacific Companion Animal, Water, Livestock, Poultry and Dairy Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions with increasing responsibilities at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to May 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.

What is the salary of Kathy Turner?

As the Corporate Vice President and Chief Marketing Officer of Idexx Laboratories, the total compensation of Kathy Turner at Idexx Laboratories is 2,696,820$. There are 3 executives at Idexx Laboratories getting paid more, with Jonathan Ayers having the highest compensation of 8,309,800$.

How old is Kathy Turner?

Kathy Turner is 56, she's been the Corporate Vice President and Chief Marketing Officer of Idexx Laboratories since 2020. There are 16 older and 7 younger executives at Idexx Laboratories. The oldest executive at Idexx Laboratories, Inc. is M. Anne Szostak, 69, who is the Independent Director.

What's Kathy Turner's mailing address?

Kathy's mailing address filed with the SEC is ONE IDEXX DRIVE, , WESTBROOK, ME, 04092.

Insiders trading at Idexx Laboratories

Over the last 22 years, insiders at Idexx Laboratories have traded over 238,711,289$ worth of Idexx Laboratories stock and bought 24,695 units worth 3,109,424$ . The most active insiders traders include Stuart Essig、Johnny D Powers、Jonathan W Ayers. On average, Idexx Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of 4,641,291$. The most recent stock trade was executed by M Anne Szostak on 5 September 2024, trading 500 units of IDXX stock currently worth 234,685$.

What does Idexx Laboratories do?

idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an

Complete history of Ms. Turner stock trades at Idexx Laboratories

Idexx Laboratories executives and stock owners

Idexx Laboratories executives and other stock owners filed with the SEC include:

• Jonathan Ayers,
  Director
• Jonathan Mazelsky,
  President, Chief Executive Officer, Director
• Brian McKeon,
  Chief Financial Officer, Executive Vice President, Treasurer
• Kathy Turner,
  Corporate Vice President and Chief Marketing Officer
• Jonathan J. Mazelsky,
  Pres, CEO & Director
• Sharon Underberg,
  Corporate Vice President, General Counsel, and Corporate Secretary
• Michael Lane,
  Executive Vice President, General Manager, Reference Laboratories and Information Technology
• Brian P. McKeon,
  CFO, Exec. VP & Treasurer
• Giovani Twigge,
  Chief Human Resource Officer, Corporate Vice President
• Dr. Nimrata Khatra Hunt P.E., Ph.D.,
  Exec. VP and GM - Point of Care Diagnostics & Worldwide Operations
• Michael J. Lane,
  Exec. VP and GM of Reference Laboratories & Information Technology
• James F. Polewaczyk,
  Exec. VP & Chief Commercial Officer
• Sharon E. Underberg,
  Exec. VP, Gen. Counsel, & Corp. Sec.
• Lawrence Kingsley,
  Independent Chairman of the Board
• M. Anne Szostak,
  Independent Director
• Daniel Junius,
  Independent Director
• Bruce Claflin,
  Independent Director
• Rebecca Henderson,
  Independent Director
• Sophie Vandebroek,
  Independent Director
• Stuart Essig,
  Independent Director
• Sam Samad,
  Independent Director
• Jonathan W. Ayers,
  Sr. Advisor & Director
• Asha Collins,
  Independent Director
• James Polewaczyk,
  Executive Vice President and Chief Commercial Officer
• Tina Hunt,
  Executive Vice President, General Manager, Point of Care Diagnostics and Worldwide Operations
• Dr. Martin Smith Ph.D.,
  Exec. VP & CTO
• Ken Grady,
  Sr. VP & Chief Information Officer
• Martin Smith,
  Exec. VP & CTO
• Jeffery D. Chadbourne,
  Sr. Director of Accounting & Financial Reporting
• John Hart,
  Sr. VP of Worldwide Operations
• Barry C Johnson,
  Director
• Thomas Craig,
  Director
• William End,
  Director
• Jacqueline Studer,
  CVP, Gen. Counsel & Secretary
• Thomas J Dupree,
  Corporate Vice President
• Michael J Williams,
  Corporate Vice President
• Daniel V Meyaard,
  Corporate Vice President
• Conan R Deady,
  Vice President and Secretary
• Joseph V Vumbacco,
  Director
• William E Iii Brown,
  Corporate Vice President
• William B. Goodspeed,
  Corporate Vice President
• Robert J Murray,
  Director
• Jeffrey Fiarman,
  EVP, GEN COUNSEL & SECRETARY
• Ali Naqui,
  Vice President
• Johnny D Powers,
  Corporate Vice President
• Errol B Desouza,
  Director
• William C Wallen,
  SVP & Chief Scientific Officer
• Quentin J Tonelli,
  Vice President
• S Sam Fratoni,
  Vice President
• Irene C Kerr,
  Corporate Vice President
• Robert S Hulsy,
  Vice President
• Laurel E Labauve,
  Vice President
• Merilee Raines,
  Vice President,CFO & Treasurer
• James L Jr Moody,
  Director
• Jennifer A Joiner,
  Corp VP CAG N American CommOps
• Louis W Pollock,
  Senior Vice President
• Erwin R Jr Workman,
  Executive Vice President
• Nimrata Hunt,
  Executive Vice President
• Irene Chang Britt,
  Director
• Martin Alexander Smith,
  Executive Vice President
• Michael Perkins Johnson,
  EVP and CHRO
• George Fennell,
  SVP, Chief Revenue Officer
• Michael G Erickson,
  Executive Vice President
• Michael Schreck,
  Executive Vice President